Dr. Nasser Altorki: Neoadjuvant Immunotherapy and Radiation Boosts Responses in NSCLC

The FDA’s CTGTAC voted that the data from the IGNYTE trial are evaluable and clinically meaningful for RP1/nivolumab in advanced cutaneous melanoma.

Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma, a cancer with few treatment options, to identify new treatment vulnerabilities.

The FDA has granted priority review to subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck cancer.

The FDA has granted orphan drug designation to enzomenib for acute lymphoblastic leukemia.

Leukocyte interleukin injection improved OS in patients with oral cancer expressing low tumor PD-L1 levels.

Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.

Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain

The Cellular, Tissue, and Gene Therapies Advisory Committee will review Replimune’s twice-rejected BLA for RP1 plus nivolumab in advanced melanoma.